Vimta Labs LimitedQuarter Ended Sep 30 2026 Results & Financial Update
Vimta Labs Limited: Quarter Ended Sep 30 2026 standalone results and company financials – revenue ₹111.98 Cr, PAT ₹20.61 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Vimta Labs price & chart
Market price₹484.90
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Vimta Labs Quarter Ended Sep 30 2026 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Profit after tax (PAT) for Q2 FY27 reached ₹20.61 crore, representing a 3.5% growth compared to ₹19.92 crore reported in Q2 FY26. Sequentially, PAT moderated by 2.0% from ₹21.04 crore registered in Q1 FY27, while total income advanced by 1.8% sequentially from ₹112.89 crore.
Management highlighted the commencement of revenue from biologics contract research and development (CRAD) services as a strategic milestone broadening the company's scientific capabilities. Pharmaceutical and food testing services continued to anchor overall business growth during the half-year period.
For the half year ended September 30, 2026 (H1 FY27), total income reached ₹227.8 crore, up 11.8% year-on-year, while EBITDA expanded 13.2% to ₹81.9 crore with a margin of 36.0%. H1 FY27 PAT rose 7.3% to ₹41.7 crore.
01 · Business model
What does Vimta Labs do?
Vimta Labs Limited, established in 1984 and headquartered in Hyderabad, India, is a contract research and testing organization (CRTO). The company provides scientific, technical, and regulatory services across analytical testing, drug discovery, clinical research, preclinical studies, and environmental assessments.
The enterprise operates extensive laboratory infrastructure spanning approximately 600,000 square feet across 10 locations and offices in India, backed by a multidisciplinary team of over 1,400 professionals. Its service portfolio caters to diverse sectors including pharmaceuticals, biopharmaceuticals, food and agriculture, medical devices, specialty chemicals, electronics, and consumer products.
Revenue generation is anchored by pharmaceutical analytical testing, clinical and preclinical research, and food and environment testing services. The company maintains regulatory compliance and accreditations from bodies such as the USFDA, CDSCO, WHO, NABL, and FSSAI, serving domestic corporations as well as international clients.
02 · Historical context
What shaped the business before this quarter
Founded in 1984 as a single bench laboratory in Hyderabad, the company has grown over four decades into a multi-facility CRTO with around 600,000 square feet of laboratory space.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Quarter Ended Sep 30 2026 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹111.98 Cr | ₹101.85 Cr | ₹109.07 Cr |
| Total income | ₹114.89 Cr | ₹104.51 Cr | ₹112.89 Cr |
| Profit before tax | ₹27.53 Cr | ₹26.27 Cr | ₹28.34 Cr |
| Profit after tax | ₹20.61 Cr | ₹19.92 Cr | ₹21.04 Cr |
| EPS | ₹4.61 | ₹4.46 | ₹4.71 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 18.4% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 24.6% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹2.90 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
The initiation of commercial revenue from newly introduced biologics contract research and development services added a fresh monetization stream during the quarter.
What drove margins
EBITDA margin held firm at 35.5% for Q2 FY27 compared to 35.3% in Q2 FY26, supported by operating efficiencies despite sequential wage and input cost movements.
Employee benefit expenses formed the largest cost component at ₹30.7 crore, followed by material and testing costs at ₹26.2 crore and other operational expenses at ₹17.3 crore.
05 · Demand, customers & order book
Where demand is coming from
The company maintains long-term service relationships with leading pharmaceutical, agro-chemical, food processing, medical device, and electronics enterprises globally.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company maintained its #1 market position in India for pharma analytical testing, serving 90% of India's top 20 pharmaceutical companies with approximately 40% of revenues derived from overseas markets.
Ranked among the top two in India for food and environment testing, the segment serves seven of India's top ten food companies, major public sector undertakings, and is the sole private EU commission-approved laboratory in India.
The preclinical division ranked among the top three in India as an integrated provider of non-clinical drug discovery services, while clinical research derived roughly 75% of its revenues from international markets.
Geography and market mix
Operations are anchored by headquarters and major facilities in Hyderabad, complemented by specialized regional testing laboratories across Ahmedabad, Noida, Mumbai (NFL), Nashik, Bengaluru, Nellore, and Kolkata.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Maintains approximately 600,000 square feet of ultra-modern laboratory space across 10 locations, featuring Gold LEED certified vivarium facilities with scalable capacities.
Projects, capex and execution
Capital expenditure (cash outflow) for Q2 FY27 stood at ₹9.2 crore (₹92 million), supporting ongoing laboratory infrastructure enhancements and technological upgrades.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Strategic focus remains centered on expanding capabilities in biologics CRAD, complex generics, biosimilars, medical device testing, and specialized environmental assessments.
09 · Reported developments
What changed operationally
Total income grew 9.9% year-on-year to ₹114.89 crore, accompanied by a 3.5% increase in PAT to ₹20.61 crore for Q2 FY27.
Successful commercial rollout of biologics contract research and development services broadened the company's addressable scientific market.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Cash and cash equivalents (including other bank balances) stood at ₹70.1 crore (₹701.12 million) as of September 30, 2026.
Capital allocation & funding
Total debt stood low at ₹14.43 crore (₹144.34 million) as of September 30, 2026, reflecting a strong debt-to-equity profile.
11 · Beyond the numbers
What changed beyond the numbers
Reported update
Regulatory Track Record
The company has successfully cleared approximately 100 regulatory audits from global and domestic bodies including USFDA, CDSCO, WHO, and NABL over its operational history.
12 · Previous-quarter changes
What changed since the previous quarter
Total income rose 1.8% sequentially from ₹112.89 crore in Q1 FY27 to ₹114.89 crore in Q2 FY27, while PAT adjusted slightly by 2.0% from ₹21.04 crore to ₹20.61 crore.
13 · Key Q&A
The quarter, answered directly
What does Vimta Labs do?
Vimta Labs Limited, established in 1984 and headquartered in Hyderabad, India, is a contract research and testing organization (CRTO). The company provides scientific, technical, and regulatory services across analytical testing, drug discovery, clinical research, preclinical studies, and environmental assessments.
What is the clearest takeaway from Quarter Ended Sep 30 2026?
Profit after tax (PAT) for Q2 FY27 reached ₹20.61 crore, representing a 3.5% growth compared to ₹19.92 crore reported in Q2 FY26. Sequentially, PAT moderated by 2.0% from ₹21.04 crore registered in Q1 FY27, while total income advanced by 1.8% sequentially from ₹112.89 crore.
What drove revenue or demand?
The initiation of commercial revenue from newly introduced biologics contract research and development services added a fresh monetization stream during the quarter.
What mattered most for margins or profitability?
EBITDA margin held firm at 35.5% for Q2 FY27 compared to 35.3% in Q2 FY26, supported by operating efficiencies despite sequential wage and input cost movements.
What changed operationally beyond the headline numbers?
Maintains approximately 600,000 square feet of ultra-modern laboratory space across 10 locations, featuring Gold LEED certified vivarium facilities with scalable capacities.
What should the next disclosure help confirm?
Execution progress and revenue scaling from the newly established biologics CRAD services division.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Biologics Ramp-Up: Execution progress and revenue scaling from the newly established biologics CRAD services division.
- 02
Margin Trajectory: Sustenance of EBITDA margins near the 35.5% level amid ongoing capital investments and scaling operational expenses.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.